Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Patient enrollment complete for sustained release AMD therapy trial ➤ First patient dosed with corneal endothelial cell substitute ➤ First patient dosed in RNAi therapy for wet and dry AMD ➤ Study: early signs of corneal graft rejection reversed with steroid nanoparticle ➤ Company announces anti-VEGF market tracker ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Allogenic cell therapy receives regulatory approval for bullous keratopathy indication ➤ 24-month data on AMD photobiomodulation therapy ➤ Patient enrollment complete for Phase 3 trial evaluating topical presbyopia treatment ➤ Pre-IND meeting for treatment of corneal endothelial disease ➤ IND submitted for geographic atrophy treatment ➤ Second Phase 3 trial for dry eye disease therapy ➤ ASCRS news and events
➤ Positive preclinical results for non-viral gene therapy platform ➤ Real-world data confirms efficacy of investigational LHON therapy ➤ Largest genome wide study of photoreceptor cells to date ➤ CDC continues to investigate infectious outbreak associated with artificial tear use ➤ Updates from AAV-based gene therapy program for retinal conditions ➤ ASCRS news and events
➤ Results from investigational non-incisional glaucoma treatment ➤ Study: preservative-free latanoprost efficacy similar to preserved alternative ➤ FDA accepts priority review NDA for vitreoretinal lymphoma treatment ➤ Companies partner to develop dry eye drop ➤ Company announces lead asset in its agonist antibody pipeline ➤ ASCRS news and events
➤ NDA submitted for sustained-release travoprost implant ➤ BLA for wet AMD, DME, DR treatment accepted with priority review ➤ Topline results from 12-month safety clinical trial for investigational dry eye drug ➤ Companies collaborate for research on sustained release for investigational GA drug ➤ ASCRS news and events
➤ First FDA-approved treatment for geographic atrophy ➤ FDA accepts NDA for presbyopia drop ➤ NDA for geographic atrophy drug accepted with priority review ➤ Study: 5-year visual field data with MIGS device ➤ ASCRS news and events
➤ FDA approves first pharmacologic treatment of ROP for preterm infants ➤ FDA accepts NDA for dilation reversal drop ➤ Phase 2b results for anti-VEGF agent for wet AMD ➤ Interim results for Phase 1 study evaluating hydrogel implant for retinal diseases ➤ Data from ongoing Phase 1/2 clinical trial of gene therapy for Leber congenital amaurosis ➤ ASCRS news and events
➤ FDA accepts NDA for dry eye treatment ➤ Phase 2 study moves forward for investigational ocular autoimmune therapy ➤ Fast-track designation granted for investigational retinitis pigmentosa treatment ➤ First-in-human feasibility study data from drug-eluting IOL platform ➤ Study identifies the ‘best approach’ for anti-VEGF therapy for diabetic retinopathy ➤ ASCRS news and events
➤ FDA approves treatment for subfoveal choroidal neovascularization due to AMD ➤ IND for inherited RPE clinical trial receives FDA clearance ➤ Phase 3 clinical trial to evaluate cooling device for anesthesia prior to injections ➤ Study calls ‘long-believed theory about diabetic cataracts into question’ ➤ ASCRS news and events
➤ Alert: eye infections linked to artificial tear ➤ Phase 2 data from research targeting Sjogren’s treatment ➤ First patient dosed in Phase 1 study for epithelial defect treatment ➤ Study compares DMEK tissue preparation techniques ➤ Topline results from oral diabetic retinopathy treatment trial ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.